Evolution of the Average Target: Eli Lilly and Company

Evolution of the Target Price: Eli Lilly and Company

Changes in Analyst Recommendations: Eli Lilly and Company

e.wPwWEX2PHOGf-QsfP66Ryi1ZaIvxcFaCLaf8F7mJPn8.7bF9YBa-VbGsllJWefrejGksGsK7CTvdQpCNZfW9WDbyuFRZP94qpq2YWg~42cd8c60da6b547da5baca7e121befc4
04-10 Rothschild & Co Redburn Adjusts Price Target on Eli Lilly to $880 From $875, Maintains Neutral Rating MT
04-09 Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says MT
04-02 Eli Lilly's Foundayo Seen as Preferred Obesity Pill on Ease of Use, BofA Says MT
04-02 BofA Securities Raises Price Target on Eli Lilly to $1,294 From $1,293, Maintains Buy Rating MT
03-31 Analyst recommendations: Berkshire Hathaway, Blackrock, Eli Lilly, Unilever, Toyota… Zonebourse
03-30 Guggenheim Adjusts Price Target on Eli Lilly to $1,163 From $1,168, Maintains Buy Rating MT
03-18 Health Care Down After HSBC Cuts Lilly Rating - Health Care Roundup DJ
03-17 Analyst recommendations: Align Technology, Eli Lilly, Adobe, Salesforce… Zonebourse
03-17 HSBC Downgrades Eli Lilly to Reduce From Hold, Adjusts Price Target to $850 From $1,070 MT
03-12 Novo Nordisk Price Target Cut as Berenberg Expects Lower CagriSema Sales Amid Recent Clinical Data MT
03-11 Wolfe Research Adjusts PT on Eli Lilly to $1,325 From $1,250, Maintains Outperform Rating MT
03-09 Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB… Zonebourse
02-27 Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says MT
02-26 Guggenheim Adjusts Price Target on Eli Lilly to $1,168 From $1,161, Maintains Buy Rating MT
02-26 Eli Lilly Set to Benefit From Obesity Franchise Dominance, RBC Says MT
02-25 RBC Initiates Eli Lilly at Outperform With $1,250 Price Target MT
02-25 RBC Starts Eli Lilly Coverage at Outperform Amid Expected Obesity Portfolio 'Dominance' Until 2030 MT
02-24 Truist Securities Keeps Eli Lilly at Buy After Head-to-head Trial Results of Novo Nordisk's Obesity Drug MT
02-23 Abivax Shows Jitters Despite Promising Updates on Obefazimod Zonebourse
02-23 Novo Nordisk Plummets After Setback for Obesity Drug – Shares Hit Lowest Level Since 2021 FW
02-23 Rothschild & Co Redburn Adjusts PT on Eli Lilly to $875 From $830, Maintains Neutral Rating MT
02-19 Berenberg Ups Estimates, Price Target on Eli Lilly Amid 'Premium Growth, Premium Valuation' MT
02-19 Berenberg Adjusts Price Target on Eli Lilly to $1,050 From $950, Maintains Hold Rating MT
02-18 Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) used together delivered superior efficacy in first-of-its-kind phase 3b trial RE
02-18 Daiwa Securities Adjusts Price Target on Eli Lilly to $1,250 From $1,230, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+28.76%
+1.45%
+19.76%
+7.36%
+6.46%
-0.37%
+0.19%
+13.57%
+28.72%
Average +11.77%
Weighted average by Cap. +13.53%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
939.47USD
Average target price
1,209.69USD
Spread / Average Target
+28.76%
High Price Target
1,500.00USD
Spread / Highest target
+59.66%
Low Price Target
850.00USD
Spread / Lowest Target
-9.52%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Rothschild & Co Redburn
BofA Securities
Guggenheim
HSBC
Wolfe Research
RBC Capital Markets
Berenberg Bank
Daiwa Securities
CICC Research
Deutsche Bank Securities
Argus
Morgan Stanley
Truist Securities
Leerink Partners
Scotiabank
Goldman Sachs
BMO Capital
Cantor Fitzgerald
JPMorgan Chase
Wells Fargo Securities
TD Cowen
Jefferies & Co.
UBS
Bernstein
Citigroup
China Merchants
DBS Bank
First Shanghai
Redburn Atlantic
JEFFERIES Akash Tewari
Barclays
China International Capital
DZ Bank
Morningstar
Credit Suisse
SVB Securities LLC
Cowen
Mizuho Securities
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
939.47USD
Average target price
1,209.69USD
Spread / Average Target
+28.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. LLY Stock
  4. Consensus Eli Lilly and Company